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ABSTRACT 
 
A simple, economical, rapid, accurate, precise spectrophotometric method has been developed and vali-
dated according to ICH Guidelines for the Mirabegron as active pharmaceutical ingredient (API) by UV spec-
trophotometric method. Estimation of Mirabegron was achieved by UV method. After considering the solu-
bility and stability, 1N Hcl was selected as solvent. The UV spectrophotometric λ value limit is 200-400. The 
absorption maxima of Mirabegron was found to be at 249 nm wavelength using 1N Hcl as a solvent. These 
solvents are color less. The precision of an analytical method is the degree of agreement among individual 
test results when the method is applied repeatedly to multiple samplings of homogenous samples. Linearity 
range was found to be 3-15μg/ml, with the correlation coefficient being more than 0.999. Slope (0.0387) 
and intercept (0.0079333), LOD (0.187 µg/ml) and LOQ (0.568 µg/ml) were calculated. The LOD and LOQ 
method was further studied by intraday and interday analysis. The relative standard deviation was found 
to be < 2%. The percentage recovery was within the range of 98% -105%, indicating that there is no signif-
icant interference from the other ingredients present in the formulation. The method can be applied for the 
routine analysis of Mirabegron as API in pharmaceutical preparation. 
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INTRODUCTION 
Overactive bladder [OAB], defined by the Interna-
tional Continence Society as urgency with or without 
urinary incontinence, usually associated with fre-
quency and nocturia[1], is a multifactorial and com-
mon health disorder associated with detrimental ef-
fects on quality of life and huge economic burden[2,3]. 
Mirabegron, sold under the brand name Myrbetriq 
among others, is a medication used to treat overac-
tive bladder[4]. Its benefits are similar to other anti-
muscarinic medication such as solifenacin or toltero-
dine[5]. In the United Kingdom it is less preferred to 
antimuscarinic medication such as oxybutynin[6]. It is 
taken by mouth[4]. Mirabegron, a selective β3-adreno-
ceptor (AR) agonist[7] , is a first in class drug for the 
treatment of OAB. Common side effects include high 
blood pressure, headaches, and urinary tract infec-
tions[4]. Other significant side effects include urinary 
retention, irregular heart rate, and angioedema. It 
works by activating the β3 adrenergic receptor in the 
bladder, resulting in its relaxation[4][6]. 
Mirabegron was approved for medical use in the 
United States in 2012[9][10][11]. A month supply in the 
United Kingdom costs the NHS about £29 as of 
2019[9]. In the United States the wholesale cost of this 
amount is about 369 USD[12].  In 2016 it was the 263rd 
most prescribed medication in the United States with 
more than a million prescriptions[13, 14]. 
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MATERIALS AND METHODS 
Selection of Solvent 
The solubility of Mirabegron was determined in a va-
riety of solvents as per Indian Pharmacopoeia stand-
ards18. Solubility test was carried out in different po-
lar and non-polar solvents from the solubility studies, 
1N Hcl was selected as suitable solvent for proposed 
method. 
Preparation of Standard Stock Solution 
Standard stock solution was prepared by dissolving, 
accurately measured 10mg of Mirabegron in 1N Hcl 
and the volume was made up to 10 ml in 10 ml volu-
metric flask (10 stock solution, 1000μg/ml). 
Determination of Absorbance Maxima 
1 ml of 10 stock solution was diluted to 10 ml with 1N 
Hcl (20 stock solution, 100μg/ml). 1 ml of 20 stock 
solution was taken in 10 ml standard volumetric flask 
dilute to 10 ml with 1N Hcl to get the concentration of 
10μg/ml. The absorbance of resulting solution was 
measured against respective blank solution (1N Hcl) 
in the UV region of 200-400 nm, which shows maxi-
mum absorbance at 249 nm. 
Determination of concentration range 
For preparation of different concentrations, aliquots 
of stock solution of suitable concentrations of Mira-
begron were transferred into a series of 10 ml stand-
ard flasks and volumes were made up to mark with 
1N Hcl. Five different concentrations were prepared 
in the range of 3-15μg/ml and the absorbance were 
measured at 249 nm against solvent (1N Hcl) blank. 
The obtained absorbance values are plotted against 
the concentrations of Mirabegron to get the calibra-
tion graph.  
Analysis of Formulation 
Twenty tablets weighed and determined the average 
of each tablet, powdered tablet equalent to 10 mg was 
transferred into 10 ml standard volumetric flask. The 
content was dissolved in 5ml of 1N Hcl. This solution 
was sonicated for 5 mins and volume made up to 
10ml. This solution was filtered through Whatmann 
filter paper number 40. One ml of the above solution 
was diluted to 10 ml with 1N Hcl. Again 1ml of the so-
lution was diluted to 10ml with 1N Hcl in 10 ml std. 
volumetric flask and the absorbance of the solution 
was measured at 249nm and the amount was found 
by using slope and intercept from the calibration 
curve. 
Precision 
The precision of an analytical method is the degree of 
agreement among individual test results when the 
method is applied repeatedly to multiple samplings 
of homogenous samples.  
Intraday and interday precision 
A variation of results within the same day (intra-day), 
variation of results between days (inter- day) was an-
alyzed. Intra-day precision was determined by ana-
lyzing Mirabegron for six time in the same day at 249 
nm. Inter-day precision was determined by analyzing 
the drug daily once for six days at 249 nm. 
Recovery studies 
In order to study the accuracy, powder of Mirabegron 
was taken, and used to carry out the analysis. Recov-
ery studies were carried out by addition of standard 
drug solution to the sample at 3 different concentra-
tion levels (50%, 100% and 150%) and the percent-
age recovery was determined by using the formula. 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑
Amount of drug added
× 100 
Limit of Detection (LOD) and Limit of Quantifica-
tion (LOQ) 
Preparation of calibration curve from the serial dilu-
tions of standard was repeated for six times. The limit 
of detection and limit of quantification was calculated 
by using the average value of slope and standard de-
viation of intercept.              
RESULTS AND DISCUSSION 
A simple, precise, accurate and reproducible method 
was developed for the estimation of Mirabegron in 
bulk and tablet formulation. Mirabegron was pro-
cured from MSN Pvt, Hyderabad and melting point 
(138-140˚C) was recorded to check the identification 
of the drug and was given (Table1).  
 
Figure 1: Ultra violet absorption Spectrum of Mira-
begron Using 1N Hcl 
Table 1: Identification of Drug by Melting Point 
S.No Identification No Standard Test 
1 Melting Point 138-140˚ 140˚ 
The solubility of Mirabegron was determined in a va-
riety of solvent ranging from no polar to polar using 
an essentially a method of Schefter and higuchi. The 
drug was found to be very soluble in 1N Hcl. Solubility 
profile of Mirabegron was given (Table 2). 10mg of 
Mirabegron raw material was accurately weighed 
and transferred into the 10ml volumetric flask and 
dissolved minimum quantity of 1N Hcl and made up 
to 10ml with 1N Hcl  solution, resulting in 1000μg/ml 
of drug concentration and form this solution 1ml was 
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pipetted out into 10ml volumetric flask and made up 
to the mark with 1N Hcl solution resulting in 
100μg/ml of drug concentration and  from this  
Table 2: Solubility profile 
S.No Solvent 
Solubility 
(mg/µl) 
Solubility Sta-
tus 
1. 1 N Hcl 200 Soluble 
2. Methanol 10 Very Soluble 
3. Ethanol 10 Very Soluble 
4. Butanol 8 Very Soluble 
5. CHCl3 50 Freely Soluble 
6. 
Dimethyl Forma-
mide 
10 Very Soluble 
solution 1ml was pipette out into 10ml volumetric 
flask and made up to the mark with 1N Hcl solution. 
It was scanned in the range of 200-400nm and it 
showed constant λmax at 249 nm and show in fig.1. 
Stability of the observance at λmax 249 nm was also 
checked for up to 1 hr and 30 min. The linearity of the 
drug Mirabegron was found, its calibration curve was 
constructed and is shown in (Figure 2). 
 
Figure 2: Calibration curve of Mirabegron by UV 
method using 1N Hcl 
Table 3: Optical characteristics of Mirabegron by UV 
method 
Parameters Values 
λ max  (nm) 249 
Beers Law limits (μg / ml) 3-15 
Regression equation (Y) Y= 0.0387X+(-0.0079333) 
Slope (m) 0.0387 
Intercept (C) 0.0079333 
Correlation coefficient (r2) 0.9992 
The optical characteristics such as beer’s law limits 
(3-15μg/ml), correlation coefficient (0.999), slope 
(0.0079333) and intercept (0.0387) were calculate 
and shown in (Table 3). Each tablet (Betmiga) con-
taining 50 mg of Mirabegron was taken and the aver-
age weight of each tablet were found and powdered. 
The powdered tablet equivalent to 10 mg of Mira-
begron was weighed and transfer into a 10ml volu-
metric flask, sufficient quantity 5ml 1N Hcl in soni-
cated for 5min and made up to the mark with 1N Hcl. 
The solution was filtered through whatmann filter 
paper 40. From clear solution, further dilution was 
made by using 1N Hcl solution, the amount of Mira-
begron present in tablet formulation was found 
(52.25). The amount found was in good agreement 
with the label claim and the results of analysis were 
shown in (Table 4). 
Table 4: Quantification of formulation – Betmiga by 
UV method 
S. 
No 
Labeled 
amount 
Amount                  
found (mg) 
Percentage 
obtained 
1 50 52.25 104.5 
 
The precision of method was confirm intraday and in-
terday analysis. The analysis of formulation was car-
ried out 6 times in the same day and daily once in the 
six consecutive days. The percentage of RDS value 
was found to be 0.0028 and 0.00306 for intraday and 
interday analysis of Mirabegron respectively. The re-
ports of analysis were shown in (Table 5). 
To evaluate the accuracy of the method, known 
amount of pure drug was added to the previously an-
alyzed solution containing pharmaceutical formula-
tion and the mixture was analyzed by the proposed 
method and the recoveries were calculated. The per-
centage recovery of Mirabegron sample was found to 
be 98% to 105%. The amount of the drug recovered 
from the formulation was very close to the expected 
value and the %RSD value also very low (0.055), this 
indicates that this method is very accurate. The re-
covery data was shown in Table 6. The limit of detec-
tion (0.187) and limit of quantification (0.568) was 
calculated by using the average value of slope and 
standard deviation of intercept. 
CONCLUSION 
Estimation of Mirabegron was achieved by UV 
method. After considering the solubility and stability, 
1N Hcl was selected as solvent. Mirabegron 10µg/ml 
solution was prepared and scanned in the UV-region, 
from the spectra 249nm was selected as an analyzing 
wavelength.   
Calibration curve was plotted by using concentration 
Vs absorbance. From the calibration curve it was 
found that Mirabegron obeys beer’s law in the range 
of 3-15µg/ml, correlation coefficient (0.999), slope 
(0.0387) and intercept (0.0079333), LOD (0.187 
µg/ml) and LOQ (0.568 µg/ml) were calculated. The 
percentage of Mirabegron in formulation was found 
to be 104.5% the precision of the method was studied 
by making repeated analysis. The LOD and LOQ 
method was further studied by intraday and interday 
analysis. The recovery studies were also carried out 
to ensure the accuracy of the method by adding 
known concentration of pure drug reanalyzed formu-
lation. 
A simple, rapid and accurate analytical method was 
developed for the determination of Mirabegron in 
bulk and tablet formulation by UV spectrophotome-
ter. The method showed excellent sensitivity, accu-
racy and repeatability, which is evidence by low per-
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centage relative standard deviation. The results ob-
tained in recovery studies where indicating that there 
is no interference from the excipients used in the  
formulation. Hence it is suggested that the proposed 
UV spectrometric can be effectively applied for the 
routine analysis of Mirabegron in bulk and formula-
tion in quality control analysis. 
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